May 11, 2020 / 12:54 PM / 2 months ago

BRIEF-Histogen Receives Us FDA Ind Approval To Initiate Phase 1B/2A Trial Of Hst 001 In Androgenic Alopecia

Conatus Pharmaceuticals Inc:

* HISTOGEN RECEIVES US FDA IND APPROVAL TO INITIATE PHASE 1B/2A TRIAL OF HST 001 IN ANDROGENIC ALOPECIA

* HISTOGEN - INTENDS TO INITIATE A PHASE 1B/2A CLINICAL TRIAL OF HST 001 IN Q2 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below